Premium
Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus‐like particle IgG concentration
Author(s) -
Bryan Janine T.,
Jansen Kathrin U.,
Lowe Robert S.,
Fife Kenneth H.,
McClowry Tracy,
Glass Dessa,
Brown Darron R.
Publication year - 1997
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/(sici)1096-9071(199711)53:3<185::aid-jmv1>3.0.co;2-4
Subject(s) - neutralization , virology , capsid , virus , antiserum , antibody , bovine papillomavirus , immunoassay , serotype , biology , chemistry , microbiology and biotechnology , immunology , gene , biochemistry , genome
Neutralization of virus is likely to be necessary for development of an effective prophylactic vaccine against genital human papillomavirus (HPV) infection. Two New Zealand white rabbits were immunized with purified HPV type 11 (HPV 11) virions in Freund's adjuvant. An enzyme linked immunoassay (ELISA) was used to determine the quantity of IgG which recognized the HPV 11 major capsid protein (L1 protein) virus‐like particles (VLPs) in the two anti‐HPV 11 sera (serum A and serum B). The concentration of HPV 11 L1 VLP‐specific IgG in the A and B sera were determined to be 37 and 90 μg per ml, respectively. The A and B sera were used in neutralization experiments in the athymic mouse xenograft system with known quantities of purified HPV 11 virions. The concentration of HPV 11 L1 VLP‐specific IgG required to neutralize HPV 11 was determined for each antiserum. This concentration of IgG was approximately 700 to 900 ng per ml. This study demonstrates a positive correlation between the level of HPV 11 L1 VLP‐specific IgG in animals immunized with HPV 11 virions and neutralization of HPV 11 in the athymic mouse model. Further studies are needed 1) to determine if sera or genital secretions from other species are neutralizing in the athymic mouse xenograft system, and 2) to determine if the VLP ELISA can be used as a reliable substitute for more cumbersome neutralization assays. J. Med. Virol. 53:185–188, 1997. © 1997 Wiley‐Liss, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom